Abstract: The present invention provides an antibody encoded by a gene which is present in a commonly deleted region of a chromosome in breast and ovarian cancers. A monoclonal antibody was prepared by using the protein as antigen and can be utilized in clinical fields for diagnosing cancer.
Abstract: This invention is directed to two highly purified neural calcium-activated neutral proteinase (CANP or calpain) inhibitors, known as high molecular weight calpastatin (HMWC) and low molecular weight calpastatin (LMWC). The invention also relates to recombinant DNA molecules which code for, and antibodies which bind to these proteins. The present invention is further directed to the use of these calpastatin proteins.
Abstract: Isolated CHF (also referred to cardiac hypertrophy factor or cardiotrophin-1), isolated DNA encoding CHF, hybridomas and cell lines producing antibodies to CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.
Type:
Grant
Filed:
May 17, 1995
Date of Patent:
May 6, 1997
Assignees:
Genentech, Inc., The Regents of the University of California
Abstract: The present invention relates to the role of dendritic cells in facilitating productive human immunodeficiency virus (HIV) infection. Experimentally, productive infection with HIV-1 requires that virus be administered to T cells that are activated by mitogens. This application describes a productive milieu for HIV-1 infection within the confines of normal epithelial tissue that does not require standard stimuli. The milieu consists of dendritic cells and T cells that emigrate from skin and produce distinctive stable, nonproliferating conjugates. These conjugates, upon exposure to HIV-1, begin to release high levels of virus progeny. Numerous infected syncytia, comprised of both dendritic cells and T cells, rapidly develop. A method is disclosed for the identification of agents capable of inhibiting HIV transmission and chronic infection of dendritic cells and T lymphocytes found in epithelial tissues.
Type:
Grant
Filed:
August 12, 1994
Date of Patent:
May 6, 1997
Assignee:
The Rockefeller University
Inventors:
Ralph M. Steinman, Melissa Pope, Michiel Betjes, Lloyd Hoffman
Abstract: HIV-1 peptides having at least one point mutation between position 593 and 611 of the HIV-1 gp160 amino acid sequence. The point mutation either is at position 604 or 610, or both positions. Immunoassays which utilize these peptides are provided, as well as, diagnostic test kits which contain these peptides.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
April 29, 1997
Assignee:
Abbott Laboratories
Inventors:
Dominique P. Bridon, Isaac S.-Y. Sze, deceased, David J. Daghfal, Keeve D. Jaffe, Tracey L. Colpitts
Abstract: The present invention relates to a retrovirus isolated from a chimpanzee and designated as SIV.sub.cpz-ant and to variants of this virus, having the following essential morphological and immunological properties: the virus exhibits a tropism for T4 lymphocytes, the virus does not exhibit cytopathic effect with the formation of giant cells in the lymphocytes that it infects, the virus has a diameter of approximately 130 nm, the virus possesses a magnesium dependent reverse transcriptase activity, it can be cultivated in T4 receptor-bearing immortalized cell-lines, lysates of the virus containing a p27 protein that is immunologically distinct from the p25 of HIV-1 and p19 protein of HTLV-1 on Western Blot, lysates of the virus containing a gp140 protein which is immunologically distinct from the gp120 of HIV-1 and gp140 of HTLV-1 by Western Blot analysis, the lysate of the virus contains an additional transmembrane glycoprotein with a molecular weight of 44,000 to 50,000 kD.
Type:
Grant
Filed:
February 11, 1993
Date of Patent:
April 29, 1997
Assignee:
Innogenetics, N.V.
Inventors:
Peter Piot, Guido Van Der Groen, Eric DeLaporte, Martine Peeters
Abstract: Peptides that inhibit amylin activity and that exhibit selectivity for amylin receptors relative to calcitonin and CGRP receptors are provided. These peptides may be used in the treatment of conditions where it is of benefit to reduce amylin activity, including the treatment of Type 2 diabetes mellitus, impaired glucose tolerance, obesity, insulin resistance and hypertension.
Type:
Grant
Filed:
July 21, 1993
Date of Patent:
April 29, 1997
Assignee:
Amylin Pharmaceuticals, Inc.
Inventors:
Lori Gaeta, Kevin Beaumont, Kathryn Prickett
Abstract: The present invention teaches multiple branch peptide constructions (MBPCs) formed from a core matrix to which is attached peptides derived from the V3 loop of the envelope glycoprotein of HIV-1, and including the amino acid sequence GPGR (SEQ ID NO: 5), preferably in the form GPGRAF, but which peptides preferably are free of the amino acid sequences IGPGR (SEQ ID NO: 1) or IXXGPGR (SEQ ID NO: 3), where X is an amino acid residue, and the use of such MBPCs as a therapy against HIV. The MBPCs prevent virus/cell infection and cell-to-cell virus transmission between CD4.sup.+ cells and HIV without hindering the immunogenic role of the CD4.sup.+ cells. Moreover, the MBPCs are effective in blockading both CD4 receptors on lymphocytes and macrophages and GalCer receptors on colon epithelial cells. These MBPCs are not immunogenic nor toxic at doses of their intended use (<[10.sup.-3 M]), thus allowing for them to be used therapeutically.
Type:
Grant
Filed:
June 15, 1994
Date of Patent:
April 22, 1997
Assignee:
Armel S.A.
Inventors:
Jean M. Sabatier, Abdelaziz Benjouad, Nouara Yahi, Emmanuel Fenouillet, Kamel Mabrouk, Jean-Claude Gluckman, Jurphaas Van Rietschoten, Herve Rochat
Abstract: The invention relates to peptides representing CTL epitopes from the HTLV-I envelope protein. The invention further relates to compositions, comprising the peptides, for priming a T-cell response in a subject. Furthermore, methods for priming a T-cell response by administration of the compositions to a subject and methods for evaluating the T-cell function of a patient are described.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
April 22, 1997
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: Disclosed are (1) a novel glia activating factor which has glial cell growth promoting activity; (2) a glia activating factor containing a polypeptide; (3) a DNA coding for a glia activating factor; (4) a host transformed with a vector containing the DNA and (5) a method for producing the above glia activating factor which comprises cultivating the transformant described in a medium, accumulating the glia activating factor in a culture broth, and collecting the resulting glia activating factor.
Abstract: A method for destroying residual lens epithelial cells in an eye in order to prevent the occurrence of posterior chamber opacification. A solution containing a basement membrane binding agent conjugated to a cytotoxic agent is introduced into the lens capsule. The solution is maintained in the lens capsule for a period of time sufficient to permit the basement membrane binding agent to bind to basement membranes within the lens capsule. The solution is then removed from the lens capsule, whereby a portion of the basement membrane binding agent remains bonded to basement membranes within the lens capsule, thereby exposing residual lens epithelial cells disposed on the basement membrane to the cytotoxic agent.
Abstract: Cancerous cells and HIV-infected cells secrete .alpha.-N-acetylgalactosaminidase into the blood stream, resulting in deglycosylation of serum Gc protein. This inactivates the MAF precursor activity of Gc protein, leading to immunosuppression. Thus, both .alpha.-N-acetylgalactosaminidase activity and MAF precursor activity of Gc protein in patient blood stream can serve as diagnostic and prognostic indices.In one embodiment is disclosed a process for determining macrophage activating factor precursor activity in plasma or serum of a person suspected of having cancer or HIV, comprising the step of quantifying in the plasma or serum an amount of vitamin D.sub.3 -binding protein. The determination of the macrophage activating factor precursor activity provides an indication of the patient's capability to activate its own monocytes/macrophages.
Abstract: Diseases attribute to a predominantly cell-mediated immune response, notably autoimmune diseases, can be suppressed by administering a novel conjugate of an appropriate antigen, notably an autoantigen, with antibody to an appropriate B cell surface molecule, such as IgD.
Abstract: An autocrine crystal adhesion inhibitor called CAI is an anionic, sialic acid-containing glycoprotein secreted by kidney epithelial cells that blocks adhesion of calcium oxalate monohydrate (COM) crystals to the cell surfaces. Persons may be classified according to risk of developing kidney stones, by measuring the amount of CAI in a biological sample. Treatment efficacy is also monitored by this method. CAI is administered in vivo to prevent nephrolithiasis. A rapid, simple assay to detect agents that inhibit adhesion of COM crystals to the surface of kidney epithelial cells is characterized.
Abstract: The present invention involves DNA encoding a mammalian Sp 17 protein, particularly human Sp17 protein, or antigenic peptides which are fragments thereof, along with said antigenic fragments. These proteins and peptides are useful as immunocontraceptive agents and/or for the diagnosis of autoimmune infertility. Avirulent host cells which express the antigeenic proteins or peptides and which are useful as immunocontraceptive agents are also disclosed.
Type:
Grant
Filed:
May 8, 1995
Date of Patent:
April 1, 1997
Assignee:
The University of North Carolina at Chapel Hill
Inventors:
Michael G. O'Rand, Esther E. Widgren, Richard T. Richardson, Isabel A. Lea
Abstract: An inflammatory cytokine is disclosed which has been isolated from cells that have been incubated with a stimulator material. The inflammatory cytokine comprises a protein that is capable of binding to heparin, inducing localized inflammation characterized by polymorphonuclear cell infiltration when administered subcutaneously and inducing in vitro polymorphonuclear cell chemokinesis, while lacking the ability to suppress the activity of the anabolic enzyme lipoprotein lipase, cause the cytotoxicity of cachectin/TNF-sensitive cells, stimulate the blastogenesis of endotoxin-resistant C3H/HeJ thymocytes, or induce the production of cachectin/TNF by primary thioglycollate-elicited mouse macrophage cells. A particular inflammatory cytokine MIP-1 has been isolated and has been found to comprise a peptide doublet of similar molecular weights of about 8,000 daltons, and to show a pI of about 4.6. The doublet has been resolved into its component peptides, MIP-1.alpha. and MIP-1.beta.
Type:
Grant
Filed:
March 7, 1994
Date of Patent:
April 1, 1997
Assignee:
The Rockefeller University
Inventors:
Anthony Cerami, Bruce Beutler, Stephen D. Wolpe
Abstract: The present invention provides a method and compositions for specifically delivering an effector molecule to a tumor cell. The method involves providing a chimeric molecule that comprises an effector molecule attached to a targeting molecule that specifically binds an IL-13 receptor and contacting a tumor cell with the chimeric molecule.
Type:
Grant
Filed:
March 15, 1995
Date of Patent:
March 25, 1997
Assignee:
The United States of America as represented by the Department of Health and Human Services
Inventors:
Raj K. Puri, Waldemar Debinski, Ira Pastan, Nicholas Obiri
Abstract: A method for making an monoclonal antibody specific for vitamin B12 by immunizing mice with vitamin B12-b-acid and isolating hybridomas that produce monoclonal antibodies which have an affinity constant for B12 greater than 5.times.10.sup.9 l/mol is disclosed.
Type:
Grant
Filed:
May 16, 1995
Date of Patent:
March 25, 1997
Assignee:
Boehringer Mannheim GmbH
Inventors:
Nicholas R. Hoyle, Gunter Pappert, Michael Grol, Christa Hubner-Parajsz
Abstract: Disclosed herein are inhibitors of the multicatalytic protease enzyme which are represented by the general formula: ##STR1## Constituent members and preferred constituent members are disclosed herein. Methodologies for making and using the disclosed compounds are also set forth herein.
Type:
Grant
Filed:
November 3, 1995
Date of Patent:
March 25, 1997
Assignee:
Cephalon, Inc.
Inventors:
Mohamed Iqbal, James L. Diebold, Robert Siman, Sankar Chatterjee, James C. Kauer
Abstract: Less toxic agents for reversal of heparin or low molecular weight heparin anticoagulation which are synthetic protamine-like polycationic peptides having a total cationic charge which is less than that of n-protamine. In preferred embodiments, arginine residues of n-protamine are replaced with lysine residues for ease of manufacture. Selective positively charged arginine residues have been replaced with an uncharged amino acid residue or its analog, such as glycine or glutamine, in order to reduce the total cationic charge on the polycationic peptide to the range of about [+14] to [+18], preferably [+16] to [+18]. In specific embodiments, there are sequences of 29 and 32 amino acid residues wherein 4 to 5 clusters of 2 to 4 positively charged amino acids are separated by 2 to 6 neutral amino acids. The C-terminus and the N-terminus can be modified to mitigate against in vivo degradation by carboxypeptidases and aminopeptidases. Another modification, specifically use of .alpha.
Type:
Grant
Filed:
September 8, 1994
Date of Patent:
March 25, 1997
Assignee:
University of Michigan, The Board of Regents Acting For and on Behalf of
Inventors:
Thomas W. Wakefield, James C. Stanley, Philip C. Andrews